Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses BDTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BDTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Velleca | $667,400 | $0 | $189,000 | $1,006,030 | $348,717 | $0 | $23,772 | $2,234,919 |
| President and Chief Executive Officer | ||||||||
| Sergey Yurasov | 525,600 | 0 | 189,000 | 402,348 | 212,342 | 0 | 22,806 | 1,352,097 |
| Chief Medical Officer | ||||||||
| Brent Hatzis-Schoch | 511,000 | 0 | 189,000 | 352,029 | 206,444 | 0 | 23,772 | 1,282,245 |
| Chief Operating Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Velleca | $2,234,919 | — | — | — |
| Sergey Yurasov | 1,352,097 | — | — | — |
| Brent Hatzis-Schoch | 1,282,245 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Ali Behbahani | Director | 2026-06-19 | A | 8,961 | $2 | $14,875 | Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-06-19 | A | 7,907 | 2 | 13,126 | Common | Form 4 ↗ |
| Garry E. Menzel | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ali Behbahani | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Campbell | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kapil Dhingra | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samarth Kulkarni | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brent Hatzis-Schoch | OPTION | — | — | — | — | — | $352,029 |
| Mark Velleca | RSU | — | — | — | — | — | 189,000 |
| Brent Hatzis-Schoch | RSU | — | — | — | — | — | 189,000 |
| Sergey Yurasov | RSU | — | — | — | — | — | 189,000 |
| Sergey Yurasov | OPTION | — | — | — | — | — | 402,348 |
| Mark Velleca | OPTION | — | — | — | — | — | 1,006,030 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brent Hatzis-Schoch | $189,000 | $0 | $352,029 | 0.0% |
| Mark Velleca | 189,000 | 0 | 1,006,030 | 0.0% |
| Sergey Yurasov | 189,000 | 0 | 402,348 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sergey Yurasov | RSU | 75,000 | — | $182,250 |
| Sergey Yurasov | Option | 200,000 | 2.52 | — |
| Brent Hatzis-Schoch | Option | 108,334 | 4.86 | — |
| Brent Hatzis-Schoch | Option | 175,000 | 2.52 | — |
| Mark Velleca | RSU | 75,000 | — | 182,250 |
| Brent Hatzis-Schoch | Option | 58,335 | 2.92 | — |
| Brent Hatzis-Schoch | Option | 3,752 | 3.79 | — |
| Brent Hatzis-Schoch | RSU | 75,000 | — | 182,250 |
| Sergey Yurasov | Option | 31,253 | 1.69 | — |
| Mark Velleca | Option | 290,877 | 4.86 | — |
| Sergey Yurasov | Option | 72,919 | 2.92 | — |
| Mark Velleca | Option | 500,000 | 2.52 | — |
| Sergey Yurasov | Option | 121,876 | 4.86 | — |
| Mark Velleca | Option | 437,505 | 3.55 | — |
Our executive compensation program is based on a pay for performance philosophy.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Human Capital Solutions (Aon plc) |
| Clawback policy | True |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-26 | 35,071,684 | 1,243,945 | 154,527 | 96.57% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-26 | 96.57%a |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of Proposal No.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Samarth KulkarniIndependent · Lead Independent Director · Nominating/Governance | $69,000 | $0 | $57,030 | $0 | $0 | $126,030 |
| Garry E. MenzelIndependent · Audit (Chair) · Compensation | 60,000 | 0 | 57,030 | 0 | 0 | 117,030 |
| Ali BehbahaniIndependent · Audit · Compensation (Chair) | 57,500 | 0 | 57,030 | 0 | 0 | 114,530 |
| Prakash RamanIndependent · Audit · Nominating/Governance | 51,500 | 0 | 57,030 | 0 | 0 | 108,530 |
| Shannon CampbellIndependent · Compensation · Nominating/Governance | 51,000 | 0 | 57,030 | 0 | 0 | 108,030 |
| Kapil DhingraIndependent · Nominating/Governance (Chair) | 48,000 | 0 | 57,030 | 0 | 0 | 105,030 |
| Mark A. VellecaEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $57,030 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $337,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $337,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Black Diamond Therapeutics | 2025 | Mark Velleca | $667,400 | $189,000 | $1,006,030 | $348,717 | $2,234,919 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Velleca | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “2025 Summary Compensation Table”. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040 |
| 2 | Section 01, Sergey Yurasov | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “2025 Summary Compensation Table”. As printed: 1,352,097. Filing ↗machine: r5 · c41 · span 388471–388480 |
| 3 | Section 01, Brent Hatzis-Schoch | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “2025 Summary Compensation Table”. As printed: 1,282,245. Filing ↗machine: r3 · c41 · span 379278–379287 |
| 4 | Section 03, Brent Hatzis-Schoch OPTION | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r3 · c23 · span 377653–377660 |
| 5 | Section 03, Mark Velleca RSU | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r1 · c17 · span 367401–367408 |
| 6 | Section 03, Brent Hatzis-Schoch RSU | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r3 · c17 · span 377114–377121 |
| 7 | Section 03, Sergey Yurasov RSU | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r5 · c17 · span 385851–385858 |
| 8 | Section 03, Sergey Yurasov OPTION | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r5 · c23 · span 386504–386511 |
| 9 | Section 03, Mark Velleca OPTION | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t8 · r1 · c23 · span 368056–368065 |
| 10 | Section 07, pay ratio | 10-K | 2026-03-16 | 0001701541-26-000009 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Samarth Kulkarni | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 126,030. Filing ↗machine: t6 · r4 · c17 · span 321603–321610 |
| 12 | Section 08, Garry E. Menzel | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 117,030. Filing ↗machine: t6 · r5 · c17 · span 323925–323932 |
| 13 | Section 08, Ali Behbahani | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 114,530. Filing ↗machine: t6 · r1 · c17 · span 315273–315280 |
| 14 | Section 08, Prakash Raman | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 108,530. Filing ↗machine: t6 · r6 · c17 · span 325922–325929 |
| 15 | Section 08, Shannon Campbell | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 108,030. Filing ↗machine: t6 · r2 · c17 · span 317280–317287 |
| 16 | Section 08, Kapil Dhingra | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 105,030. Filing ↗machine: t6 · r3 · c17 · span 319603–319610 |
| 17 | Section 08, Mark A. Velleca | DEF 14A | 2026-04-29 | 0001104659-26-051474 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 02, Ali Behbahani 2026-06-19 | Form 4 | 2026-06-22 | 0001193125-26-277553 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Prakash Raman 2026-06-19 | Form 4 | 2026-06-22 | 0002018686-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Garry E. Menzel 2026-06-26 | Form 4 | 2026-06-29 | 0001556064-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Prakash Raman 2026-06-26 | Form 4 | 2026-06-29 | 0002018686-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Ali Behbahani 2026-06-26 | Form 4 | 2026-06-29 | 0001193125-26-288598 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Shannon Campbell 2026-06-26 | Form 4 | 2026-06-29 | 0002018966-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Kapil Dhingra 2026-06-26 | Form 4 | 2026-06-29 | 0001456849-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Samarth Kulkarni 2026-06-26 | Form 4 | 2026-06-29 | 0001682019-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 06, 2026 vote | Form 8-K | 2026-06-29 | 0001104659-26-078847 | Item 5.07 · say-on-pay result. As reported: 96.57% (votes for as printed: 35,071,684). Filing ↗ |
| 27 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 28 | Section 09b board cost (computed) | Computed | — | computed | Cash 337,000 + equity 0 + all other 0 = 337,000, summed across the director compensation table rows.machine: formula: Σ = 337,000 |
| 29 | Black Diamond Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-051474 | CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040 |